NCT02612714 is a Phase 4 clinical trial of Rosuvastatin in Sexual Dysfunction, sponsored by Chang Gung Memorial Hospital.

Who is sponsoring NCT02612714?

NCT02612714 is sponsored by Chang Gung Memorial Hospital.

What drugs are being tested in NCT02612714?

Interventions in NCT02612714: Rosuvastatin.

What condition does NCT02612714 study?

NCT02612714 studies Sexual Dysfunction.

Is NCT02612714 still recruiting?

NCT02612714 is currently completed. Last updated 20 November 2015.

Last reviewed 2015-11-20 · How we verify

NCT02612714

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Statin Therapy is Associated With Low Testosterone and Sexual Function in Men With Type 2 Diabetes

Completed Phase 4 Last updated 20 November 2015

What this trial tests

Phase 4 trial testing Rosuvastatin in Sexual Dysfunction in 151 participants. Completed in 1 December 2014.

Timeline

1 July 2013

Primary endpoint
1 November 2014

1 December 2014

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Enrollment	151
Start date	1 July 2013
Primary completion	1 November 2014
Estimated completion	1 December 2014
Sites	1 location across Taiwan

Drugs / interventions tested

Rosuvastatin (rosuvastatin) — full drug profile →

Conditions studied

Sexual Dysfunction — all drugs for Sexual Dysfunction →

Sponsor

Chang Gung Memorial Hospital

Who can join

Adults 18 to 75, male only, with Sexual Dysfunction. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

serum testosterone
Time frame: up to 24 weeks
The measure is a composite outcome measure consisting of multiple measures. Serum testosterone measured after 24 weeks statin treatment, after quitted statin for 24 weeks and after 24 weeks of re-administrating statin

Sponsor's own description

Statins may decrease serum testosterone levels via decreasing cholesterol. This longitudinal study detected the effects of rosuvastatin on free testosterone levels and sexual function in men with type 2 diabetes. Methods: Investigator enroll 150 men with type 2 diabetes and hypercholesterolemia. Biochemical assessments include serum total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein, triglyceride, prolactin, thyroid-stimulating hormone, luteinizing hormone, follicle stimulating hormone, total testosterone and serum sex hormone binding globulin (SHBG). All parameters are measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) are also evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Rosuvastatin

Trials testing the same drug.

NCT07474649 — A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events · Phase 3 · not yet recruiting
NCT07534592 — A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants · Phase 1 · not yet recruiting
NCT07515339 — A Study to Learn More About How Safe Nurandociguat is and How it Affects the Way the Body Processes Rosuvastatin and Dab · Phase 1 · not yet recruiting
NCT07303816 — Statins to Prevent Cancer Associated Blood Clots · Phase 4 · not yet recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting

Other recruiting trials for Sexual Dysfunction

Currently open trials in the same condition.

NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and · NA · recruiting
NCT07104292 — Pelvic Floor Muscle Training During Pregnancy · NA · recruiting
NCT06541002 — A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors · NA · recruiting
NCT06868121 — AYA OMGYES Sexual Health Study · NA · recruiting
NCT06587841 — Noninvasive Spinal Cord Stimulation for Early SCI · NA · recruiting

Other Chang Gung Memorial Hospital trials

Trials by the same sponsor.

NCT07419789 — Precision Care for Older Persons · NA · not yet recruiting
NCT07248345 — Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia · NA · not yet recruiting
NCT07036978 — Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer · not yet recruiting
NCT07489833 — Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue · not yet recruiting
NCT07496528 — The ACURE Trial: Acupuncture for Colorectal Recovery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02612714 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chang Gung Memorial Hospital
Last refreshed: 20 November 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02612714.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing